Seizures in haemodialysis patients treated with recombinant human erythropoietin.
Administration of recombinant erythropoietin (r-HuEPO) is an effective treatment for the anaemia of chronic renal failure, but in some patients it has been accompanied by elevated blood pressure. This study focuses on seven patients with end-stage renal failure, managed on haemodialysis, who developed probable hypertensive encephalopathy with seizures during treatment with r-HuEPO. All made a full recovery. The events were not clearly related to the haemoglobin concentrations achieved, and four patients have subsequently been restarted on r-HuEPO therapy at a reduced dose, resulting in a slower increase in haemoglobin with no recurrence of episodes of severe hypertension. Close attention needs to be paid to blood pressure in patients commencing erythropoietin therapy, and it seems prudent to aim for a gradual increase in haemoglobin concentration to allow the circulation to adapt to changes in oxygen delivery and haematocrit.
Edmunds
M E
ME
Department of Nephrology, Leicester General Hospital, UK.
Walls
J
J
Tucker
B
B
Baker
L R
LR
Tomson
C R
CR
Ward
M
M
Cunningham
J
J
Moore
R
R
Winearls
C G
CG
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D012640:Seizures / Q000139:chemically induced*
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin